Why Are GD Culture Shares Trading Lower Today
GD Culture Group Limited (NASDAQ:GDC) shares plunged since it shared plans to raise funds via direct stock sale. On Tuesday,…
Agnico Eagle Announces Renewal Of Normal Course Issuer Bid Of Up To 5% Of Outstanding Shares, Or Not More Then $500M
(All amounts expressed in U.S. dollars unless otherwise noted)TORONTO, May 2, 2023 /PRNewswire/ - Agnico Eagle Mines Limited (NYSE:AEM) (TSX:AEM) ("Agnico Eagle") announced today that further to its news release dated
‘Meta SEC Filing Reveals Debt Securities Offering Plans; Facebook Parent Company Filed A Prospectus That Says It May Offer And Sell Debt Securities Occasionally; Did Not Disclose The Exact Amount Of Debt Securities Being Offered’ – CoinTelegraph
https://cointelegraph.com/news/meta-sec-filing-reveals-debt-securities-offering-plansTech giant Meta, the parent company of Facebook, Instagram and WhatsApp, submitted a filing to the United States Securities and
Pulse Biosciences Announces $65M Private Placement Via 10M Shares At $6.51 Per Share With Chair Robert W. Duggan
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology and proprietary CellFX System® for the treatment of atrial
ENDRA Life Sciences Announces Pricing of Upsized $4.5M Public Offering Of 3.75M Shares Of Common Stock And Warrants To Purchase 1.875M Shares Of Common Stock
ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it has priced an underwritten public
Hillstream BioPharma Announces Proposed Public Offering; No Size Or Amount Disclosed
Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis,
Innate Pharma Establishes A New At-The-Market Program On Nasdaq; Company May Offer And Sell A Total $75M Co. ADS From Time To Time
Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has filed a prospectus supplement with the Securities and Exchange Commission ("SEC") relating
ZyVersa Therapeutics, Inc. Announces Pricing Of $11M Public Offering Of $11.015,500 Shares Of Common Stock At A Price Of $1/Share
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or ", ZyVersa", )))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, today
Mesoblast Completed A Global Private Placement Raising Approximately US$40M
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share.
MAIA Biotechnology, Inc. Announces Pricing Of $5M Public Offering Of 2,222,200 Shares Of Common Stock At A Price Of $2.25/Share
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of an